June 05, 2022
4 min watch
Save
VIDEO: Psoriasis therapies continue to improve, expand
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
CLEVELAND — At the Medical Dermatology Therapy Update II, Andrew Blauvelt, MD, MBA, gave an update on available psoriasis therapies and those on the horizon.
In this video, Blauvelt, president of the Oregon Medical Research Center, explained interleukin (IL)-17, IL-13 and tumor necrosis factor blockers currently on the market and which patients are best suited to which treatments, as well as an overview of two drugs in development to target new psoriasis pathways.
Published by:
Sources/Disclosures
Collapse
Source:
Andrew Blauvelt, MD, MBA
Disclosures:
Blauvelt reports being a speaker, advisor and/or clinical advisor for AbbVie, Abcentra, Aligos, Almirall, Amgen, AnaptysBio, Arcutis, Arena, Asian, Athenex, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, EcoR1, Eli Lilly and Company, Evommune, Forte, Galderma, Highlightll Pharma, Incyte, Janssen, Landos, LEO, Merck, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Spherix Global Insights, Sun Pharma, TrialSpark, UCB, Vibliome and Xencor.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.